These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31060635)

  • 21. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.
    Olsen CK; Brennum LT; Kreilgaard M
    Eur J Pharmacol; 2008 Apr; 584(2-3):318-27. PubMed ID: 18325493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia.
    Bisol LW; Brunstein MG; Ottoni GL; Ramos FL; Borba DL; Daltio CS; de Oliveira RV; Paz GE; de Souza SE; Bressan RA; Lara DR
    J Clin Psychiatry; 2008 Oct; 69(10):1572-9. PubMed ID: 19192440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia.
    Sakumoto N; Kondo T; Mihara K; Suzuki A; Yasui-Furukori N
    Psychiatry Clin Neurosci; 2007 Apr; 61(2):174-80. PubMed ID: 17362435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
    Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
    Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigational dopamine antagonists for the treatment of schizophrenia.
    Wang SM; Han C; Lee SJ; Jun TY; Patkar AA; Masand PS; Pae CU
    Expert Opin Investig Drugs; 2017 Jun; 26(6):687-698. PubMed ID: 28443355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current use of atypical antipsychotics.
    Müller-Spahn F
    Eur Psychiatry; 2002 Aug; 17 Suppl 4():377s-384s. PubMed ID: 23573608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Psychopharmocotherapy of schizophrenia in forensic and general psychiatry].
    Stompe T; Schanda H
    Neuropsychiatr; 2011; 25(2):75-84. PubMed ID: 21672506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Focus on ziprasidone.
    Green B
    Curr Med Res Opin; 2001; 17(2):146-50. PubMed ID: 11759185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment compliance in veterans administration schizophrenia spectrum patients treated with risperidone long-acting injectable.
    Duncan EJ; Woolson SL; Hamer RM
    Int Clin Psychopharmacol; 2012 Sep; 27(5):283-90. PubMed ID: 22644368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimisation of long-term treatment in schizophrenia: treating the true spectrum of symptoms.
    Kasper S
    Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S135-41. PubMed ID: 16872809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new framework for investigating antipsychotic action in humans: lessons from PET imaging.
    Kapur S
    Mol Psychiatry; 1998 Mar; 3(2):135-40. PubMed ID: 9577837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Less is more Redux: Scheduled intermittent dosing to protect/prevent cognitive deterioration in schizophrenia.
    Boshes RA; Manschreck TC
    Med Hypotheses; 2016 May; 90():79-81. PubMed ID: 27063092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How do we choose between atypical antipsychotics? The advantages of amisulpride.
    Mortimer AM
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S21-5. PubMed ID: 14972081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138.
    Millan MJ; Brocco M
    Therapie; 2008; 63(3):187-229. PubMed ID: 18718210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potent Dopamine D2 Antagonists Block the Reward-Enhancing Effects of Nicotine in Smokers With Schizophrenia.
    Whitton AE; Green AI; Pizzagalli DA; Roth RM; Williams JM; Brunette MF
    Schizophr Bull; 2019 Oct; 45(6):1300-1308. PubMed ID: 30690638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics.
    Mizrahi R; Mamo D; Rusjan P; Graff A; Houle S; Kapur S
    Int J Neuropsychopharmacol; 2009 Jun; 12(5):715-21. PubMed ID: 19366489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.
    Schmidt ME; Kent JM; Daly E; Janssens L; Van Osselaer N; Hüsken G; Anghelescu IG; Van Nueten L
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):721-33. PubMed ID: 22464973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Theory in antipsychotic drug therapy for schizophrenia].
    Tomioka S; Ishigooka J
    Seishin Shinkeigaku Zasshi; 2006; 108(6):614-8. PubMed ID: 16910539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Mental Well-Being in Schizophrenia: Results From the Randomized NeSSy Trial.
    Veselinović T; Scharpenberg M; Heinze M; Cordes J; Mühlbauer B; Juckel G; Rüther E; Paulzen M; Haen E; Hiemke C; Timm J; Gründer G;
    J Clin Psychopharmacol; 2019; 39(6):550-560. PubMed ID: 31688449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Psychobiological significance of antipsychotics in multi-high dose drug therapy for schizophrenia].
    Watanabe K
    Seishin Shinkeigaku Zasshi; 2006; 108(6):608-13. PubMed ID: 16910538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.